Buscar en
Revista Española de Patología
Toda la web
Inicio Revista Española de Patología A comparative study of the expression of cyclin D1, COX-2, and KI-67 in odontoge...
Información de la revista
Vol. 55. Núm. 2.
Páginas 90-95 (Abril - Junio 2022)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Visitas
348
Vol. 55. Núm. 2.
Páginas 90-95 (Abril - Junio 2022)
Original article
Acceso a texto completo
A comparative study of the expression of cyclin D1, COX-2, and KI-67 in odontogenic keratocyst vs. ameloblastoma vs. orthokeratinized odontogenic cyst
Estudio comparativo de la expresión de ciclina D1,COX-2 y Ki-67 en queratoquiste odontogénico vs. ameloblastoma vs. quiste odontogénico ortoqueratinizado
Visitas
...
Fátima Martín-Hernána,
Autor para correspondencia
fatimamartin@ucm.es

Corresponding author.
, Julián Campo-Traperob, Jorge Cano-Sánchezc, Rosa García-Martínd, Mario Martínez-Lópezd, Claudio Ballestín-Carcavillaa,b,c,d
a Universidad Complutense de Madrid, Private Practice, Madrid, Spain
b Department of Medicine and Orofacial Surgery, Universidad Complutense de Madrid, Madrid, Spain
c Inmunohistochemistry Unit 12 de Octubre University Hospital, Madrid, Spain
d Department of Pathological Anatomy 12 de Octubre University Hospital, Madrid, Spain
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Figuras (3)
Mostrar másMostrar menos
Tablas (4)
Table 1. Immunohistochemistry: primary antibodies, dilutions, clones, antibody label, buffer used and incubation time.
Table 2. COX-2 expression in the three study groups.
Table 3. Ki-67/MIB-1 expression in the three study groups.
Table 4. Cyclin D1 expression in the three study groups.
Mostrar másMostrar menos
Abstract
Background

Odontogenic keratocysts (OKCs) and orthokeratinized odontogenic Cysts (OOCs) are distinct clinicopathological entities. OKC appears to behave in a way more similar to that of a neoplasm, such as ameloblastoma (AB). The aim of this study is to compare the influence of Ki-67, Cyclin D1 and COX-2 in the diagnosis and pathogenesis of OKC, OOC and AB.

Materials and methods

A cross-sectional observational study of 41 samples was organized into 3 groups: (1) OKC n=22; (2) AB n=13 and (3) OOC n=6. Paraffin blocks were sectioned and stained with hematoxylin and eosin (H&E). Immunohistochemical study using Bond Polymer Refine Red Detection Kit, Leica, Wetzlar, Germany, was performed for the following antibodies: Ki-67, Cyclin D1 and COX-2. Double blind immunostaining was quantified subjectively. Staining: nuclear or cytoplasmic; nuclear (Ki-67 and Cyclin D1>5% positive) and cytoplasmic (COX-2; 1; 1–30 cytoplasm: 2; 31–60 cytoplasm; 3; 61–100 cytoplasm). Considering positive stained 61-100 cytoplasms.

Results

The expression of Ki-67 was higher in the OKC group than in the AB group (p<0.05). Cyclin D1 showed a higher expression in OKC vs. OOC and OKC vs. AB (p<0.05). Finally, expression of COX-2 was higher in OKC vs AB (p<0.05).

Conclusions

COX-2, Ki-67 and Cyclin D1 show statistically significant differences between the groups, suggesting that they could be useful tools in the differential diagnosis between OKCs and OOC and a predictive indicator for their biologic behaviour. The higher expressions of these 3 markers of OKC vs AB highlight once more the aggressive behaviour of this now re-considered cystic lesion. These markers could prove useful in the choice of more aggressive surgical treatment in OKCs as their behaviour appears to be similar to that of a neoplasm.

Keywords:
Odontogenic keratocyst
Ameloblastoma
Ki-67
COX-2
Cyclin D1
Resumen
Antecedentes

Los queratoquistes odontogénicos (QQO) y los quistes odontogénicos ortoqueratinizantes (QOO) son entidades clínico-patológicas diferentes y el QQO parece estar más próximo al comportamiento de una neoplasia, como el ameloblastoma (AB).

El objetivo de este estudio es comparar la influencia de Ki-67, ciclina D1, COX-2, en el diagnóstico y patogenia de QQO, QOO y AB.

Materiales y métodos

Se ha diseñado un estudio observacional transversal con 41 muestras, en 3 grupos de estudio: (1) QQO: n=22, (2) AB n=13, y (3) QOO n=6. Se han seccionado bloques de parafina y teñido con hematoxilina y eosina y sometidas a una incubación con anticuerpos monoclonales (Kit Bond Polymer Refine Detection, Leica, Wezlar, Alemania) para la realización de un estudio inmunohistoquímico. Se ha cuantificado la inmunotinción, (nuclear o citoplasmática); nuclear (Ki-67 y ciclina D1; >5% positiva) y citoplasmática (COX-2; 1; 1-30 citoplasmas; 2; 31-60 citoplasmas; 3; 61-100 citoplasmas). Considerando positivo tinción a partir de 61-100 citoplasmas.

Resultados

La expresión de Ki-67 ha sido mayor en el grupo del QQO con respecto a la de AB (p<0,05). Respecto a ciclina D1, mostró una expresión mayor en QQO vs. QOO (p<0,05); En el caso del marcador COX-2, la expresión ha sido mayor en QQO vs. AB (p<0,05).

Conclusiones

La mayor expresión de estos 3 marcadores en QQO vs. AB resaltan una vez más el comportamiento agresivo de esta lesión ahora reconsiderada como «quística». Estos marcadores pueden ayudar a decidir tratamientos quirúrgicos más agresivos en las lesiones de QQO ya que parece comportarse como una «neoplasia».

Palabras clave:
Queratoquiste odontogénico
Ameloblastoma
Ki-67
COX-2
Ciclina D1
Texto completo
Introduction

Odontogenic cysts account for 14.4% of oral biopsies of the maxillofacial area.1 They derive from the dental lamina due to genetic dysregulation in the odontogenesis process due to genetic mutations, the most important being the Patched 1 gene, (PTCH 1). Up to 40% are also derived from the reduced epithelium of the dental follicle, explaining the dentigerous origin of these lesions.2–6

In January 2017 the WHO updated its classification on head and neck tumours with regard to odontogenic and bone tumours of the maxillofacial area. Odontogenic cysts that had been eliminated from the 3rd Edition in 20057 were included again8–10 and the keratocystic odontogenic tumour (KCOT) renamed as OKC.8,11

Despite the new classification and the fact that the OKC is no longer considered by experts to be a tumour, but a cyst, the OKC and OOC are still being considered separate entities.8

AB is the most common odontogenic tumour after odontoma and has been used in the study as a control, as it has a biological pattern very similar to that of OKC.9,12,13

The role of immunohistochemistry (IHC) in OKC, OOC and AB has been intensively studied. Cell markers are proteins expressed in cells at different times of the cell cycle and help to assess the aggressive and invasive potential of lesions, mainly by measuring cell proliferation. Cell proliferation index is a prognostic marker in many types of tumours and is evaluated using histochemistry, counting the cells with a positive expression per stained field of each sample obtained. This expression is detected by IHC.14–16 These markers are essential for the diagnosis, prognosis, management and prediction of a possible recurrence or even the possibility of a malignant transformation.17–20

The Ki-67 marker is a nuclear and nucleolar protein that determines cell proliferation and is found in all active parts of the cell cycle and therefore is related to abnormal cell growth. COX-2 is an enzyme that induces the production of cytokines; it increases in OKCs and is marker for the behaviour and nature of these lesions.

Finally, Cyclin D1 is a nuclear protein that plays a crucial role in the cell cycle, allowing the progress of the DNA synthesis phase and therefore evaluates cell proliferation.14,17,21

The main objective of this study is to compare the influence of Ki-67, Cyclin D1 and COX-2 on the diagnosis and pathogenesis of OKC, OOC and AB.

Materials and methods

Forty-one blocks embedded in paraffin and fixed in formaldehyde from 1970 to 2007 inclusive, were collected by non-random sampling from the Hospital Universitario 12 de Octubre (Madrid).

Cases were reconsidered using double-blind evaluation by two specialists in pathomorphology (B.D) of H&E stained sections, according to the 2017 WHO classification, confirming: 22 OKC, 6 OOC and 13 AB of solid type.

The samples were deparaffinized and hydrated and the hydroxymethylene bridges formed between the amino-acid sequence were broken by heat treatment to expose tissue antigens using a citrate buffer (pH 6.0). The primary antibody used to recognize the desired antigen was then incubated for 20min. Table 1 summarizes the primary antibodies, dilutions, clones, antibody brand, buffer used and incubation time.

Table 1.

Immunohistochemistry: primary antibodies, dilutions, clones, antibody label, buffer used and incubation time.

Antibodies  Dilutions  Clones  Brand  Buffer  Incubation  Staining 
COX-2  1/50  CX-294  DAKO  Citrate pH 6  20min  Cytoplasmic 
MIB-1 (Ki-67)  1/100  MIB-1  DAKO  Citrate pH 6  20min  Nuclear 
CYCLIN D1  Prediluted  EP-12  Master diagnostic  Citrate pH 6  20min  Nuclear 

Subsequently, incubation was performed with the Bond Polymer Refine Detection Kit from Leica, Wetzlar, Germany, of the secondary antibody directed to the primary antibody (peroxidase-labeled polymer) and developed with Diamenobenzidine (DAB). DAB is a chromogenic chemical compound that binds to the antibody and reacts with peroxidase creating a dark brown stain in the deposits formed by the antigen-antibody complex. Finally, a brief incubation with H&E was realized to visualize the cell structure using a conventional light microscope Olympus® (Model BX43F, U-LHLEDC, Tokyo, Japón INC) at magnification 20×.

The quantification of the immunostaining was evaluated manually, the number of positive staining cells per 1000 epithelial cells was expressed as a percentage and depended on whether the staining was cytoplasmic or nuclear. For nuclear staining, such as Ki-67 and Cyclin D1, more than 5% positive nuclei was considered positive and cytoplasmic staining for COX-2 greater than 61% of cells was considered positive.

Statistic analysis

Data was analysed using SPPS version 23 and descriptive statistics were used. Pearson's Xi square and ANOVA test were performed and statistical significance was quantified with a p value<0.05.

Results

Positive results were quantified in nuclear staining (Ki-67 and Cyclin D1) (Figs. 1 and 2) when more than 5% of nuclei were positive and in cytoplasmic staining (COX-2) (Fig. 3) when greater than 61% were positive. Markers that demonstrated a positive correlation between COX-2 expression (p=0.005) are summarized in Table 2; Ki-67/MIB-1 (p=0.004) in Table 3 and Cyclin D1 (p=0.020) in Table 4. OKC versus AB presented higher values in their expression.

Figure 1.

Left: Positive expression (10% positive staining) of Ki-67 in AB, 100×. Right: Positive expression (15% positive staining) of Ki-67 in OKC, 100×.

(0,08MB).
Figure 2.

Left: Positive expression (18% positive staining) of Cyclin D1 in AB, 100×. Right: Positive expression (25% positive staining) of Cyclin D1 in OKC, 100×.

(0,11MB).
Figure 3.

Left: Negative expression (0 staining) of COX-2 in AB, 100×. Right: COX-2 Positive expression in OKC (3: 61–100% positive staining cytoplasm), 100×.

(0,11MB).
Table 2.

COX-2 expression in the three study groups.

Lesion  Expression quantificationp value <0.05 
  Negative  Positive: >5% nuclearPositive: 61–100% cytoplasm   
OKC  12 (29.2%)  0 (0%)  0.6018 
OOC  5 (12.2%)  0 (0%)  0.5127 
AB  4 (9.7%)  1 (2.4%)  0.00579 
Total  21 (51.2%)  1 (2.4%)   
Table 3.

Ki-67/MIB-1 expression in the three study groups.

Lesion  Expression quantificationp value <0.05 
  Negative  Positive: >5% nuclearPositive: 61–100% cytoplasm   
OKC  0 (0%)  22 (53.7%)  0.747 
OOC  0 (0%)  6 (14.6%)  0.002 
AB  10 (24.4%)  3 (7.3%)  0.008 
Total  10 (24.4%)  31 (75.6%)   
Table 4.

Cyclin D1 expression in the three study groups.

Lesion  Expression quantificationp value <0.05 
  Negative  Positive: >5% nuclearPositive: 61–100% cytoplasm   
OKC  3 (7.3%)  19 (46.3%)  0.004 
OOC  0 (0%)  6 (14.6%)  0.002 
AB  7 (17.1%)  6 (14.6%)  0.008 
Total  10 (24.4%)  31 (75.6%)   

Fig. 1 shows the highest expression of Ki-67 in OKC mainly in the most basal layers, with greater cell proliferation, in contrast to AB, where mainly the suprabasal layers were positive and less cell proliferation and mitoses were found. In Fig. 2 the same is observed with the Cyclin D1 marker and in Fig. 3 with the COX-2 marker.

Discussion

Despite the different quantifications of IHC expression in different studies such as Gani et al., Alsaegh et al. or Mendes et al.,21–23 the number of cells positive for Ki-67 is always higher in OKCs than in ABs or OOCs; this was also found in the present study.

De Vicente et al. found that Ki-67 expression measured in percentage for dentigerous cysts was 17%, 15.5% for radicular cysts and 7.8% in ABs. However, the percentage rose to 40% in OKCs, leading them to conclude that the cell proliferation index was significantly higher in OKCs than in other types of lesions.

This finding would also point to an intrinsic growth potential of the OKC and a defective function of the tumour suppressor genes relating to a possible mutation of the PTCH 1 gene as well as an increase in cell proliferation, leading to more aggressive behaviour of these lesions.24

Both Alsaegh et al and Mendes et al, observing ABs and OKCs respectively and comparing COX-2 expression, obtained very high percentages of positive cells. However, the mean of positive cells (for COX-2) in our research is lower, approximately ±2. A possible explanation for these differences could be that they used Clones BA0738 with a 1:100 dilution, while we used the CX-294 clone at a 1:50 dilution.22,23

Finally, Gani, Vera-Sirera et al and De Vicente et al found a high expression of Cyclin D1 in OKCs vs ABs, coinciding with our results (p<0.05).17,21.24

In conclusion, statistically significant differences have been found for all three markers, COX-2, MIB-1/Ki-67 and Cyclin D1, which would suggest that they could prove to be useful tools in the differential diagnosis between OKCs, OOCs and ABs and also in predicting the behaviour of the cystic lesions. Furthermore, they could be of help in planning more aggressive surgery for OKC lesions.

Funding

No funding was received.

Ethics approval and consent to participate

This study is approval for the ethics committee Hospital 12 de Octubre and following the Helsinki Declaration.

Conflict of interest

The authors declare that they have no competing interest

Acknowledgements

We would like to thank the pathology department of the University Hospital “12 de Octubre” for their help with this study.

References
[1]
M. Gayathri, K.R. Don.
Prevalence of odontogenic cyst. A retrospective clinico-pathological study.
Res J Sci Tech, 9 (2017), pp. 259-266
[2]
W.A. Soskolne, M. Shear.
Observations on the pathogenesis of primordial cysts.
Brit Dent J, 123 (1967), pp. 321
[3]
P.J. Stoelinga.
Etiology and pathogenesis of keratocysts.
Oral Maxillofac Surg Clinics North Am, 15 (2003), pp. 317-324
[4]
M. Shear.
The aggressive nature of the odontogenic keratocyst: it is a benign cystic neoplasm? Part 1. Clinical and early experimental evidence of aggressive behaviour.
Oral Oncol, 38 (2002), pp. 219-226
[5]
Weber AL, Kaneda T, Scrivani SJ, Aziz S. Jaw: cysts, tumors, and nontumorous lesions. In: Head and neck imaging, 4° ed. 2003. p. 930–94.
[6]
A.C. Johann, P.C. Caldeira, M.V. Caliari, M.H.N.G. de Abreu, M.C.F. Aguiar, R.A. Mesquita.
Metallothionein in the radicular, dentigerous, orthokeratinized odontogenic cysts and in keratocystic odontogenic tumor.
J Oral Pathol Med, 40 (2011), pp. 270-276
[7]
Barnes L, Eveson JW, Reichart P, Sidransky D. Tumors of the salivary glands. In: Pathology and genetics of the head and neck tumours, World Health Organization, Lyon. 2005. p. 209.
[8]
J.M. Wright, M. Vered.
Update from the 4th edition of the world health organization classification of head and neck tumours: odontogenic and maxillofacial bone tumors.
Head Neck Pathol, 11 (2017), pp. 68-77
[9]
El-Naggar AK, Chan John KC, Gradis JR, Takata T, Slootweg PJ. WHO Classification of Head and Neck Tumours. International Agency for Research on Cancer (IARC). 4° Ed. Lyon 2017. En: Vered M, Muller S, Heikinheimo K. Capítulo 8: odontogenic and maxillofacial bone tumours. 2017; 215–8; 235–41.
[10]
P.M. Speight, T. Takata.
New tumour entities in the 4th edition of the world health organization classification of head and neck tumours: odontogenic and maxillofacial bone tumours.
Virchows Archiv, (2017), pp. 1-9
[11]
C. Thereza-Bussolaro, A. Aburad, C. Pachêco-Pereira, C. Flores-Mir.
Association of treatment and a 3-D image follow-up on a recurrent keratocyst—case report.
J Oral Diag, 2 (2017), pp. 1-6
[12]
A.C. McClary, R.B. West, A.C. McClary, J.R. Pollack, N.J. Fischbein, C.F. Holsinger, et al.
Ameloblastoma: a clinical review and trends in management.
Eur Arch OtoRhinoLary, 273 (2016), pp. 1649-1661
[13]
S. Yasuoka, T. Kato.
Histopathological and immunohistochemical characteristics of the progressive front of ameloblastoma.
Int J Oral-Med Sci, 13 (2015), pp. 110-119
[14]
B. Vera-Sirera, L. Forner-Navarro, F. Vera-Sempere.
Differential expression of cyclin d1 in keratin-producing odontogenic cysts.
Med Oral Patol Oral Cir Bucal, (2014),
[15]
A. Figueroa, H. Rivera, M. Correnti.
Odontogenic keratocyst: a true odontogenic benign neoplasia or a cystic lesion?.
(2007),
[16]
Z. Kolář, M. Geierová, J. Bouchal, J. Pazdera, V. Zbořil, P. Tvrdý.
Immunohistochemical analysis of the biological potential of odontogenic keratocysts.
J Oral Pathol Med, 35 (2006), pp. 75-80
[17]
P. Fortin, M. Briend, S. Morales, A. Alsina, M. Solís.
Expresión inmunohistoquímica de PCNA Ki-67 y ciclina D1 en ameloblastomas multiquísticos.
RAOO, 52 (2014), pp. 43-49
[18]
A. Kolokhytas, R.P. Fernandes, A. Pazoki, R.A. Ord.
Odontogenic keratocyst: to decompress or not to decompress? A comparative study of decompression and enucleation versus resection/peripheral ostectomy.
J Oral Maxillofac Surg, 65 (2007), pp. 640-644
[19]
M.R. Darling, R. Woodford, K.K. Cuddy, L. Jackson-Boeters, A. Hayter, J. Inkaran, et al.
Kallikrein-related peptidase expression in odontogenic cysts and tumors: an immunohistochemical comparative study.
J Invest Clinic Dent, (2017),
[20]
P.R. Moreira, M.M. Guimarães, A.L.S. Guimarães, M.G. Diniz, C.C. Gomes, J.A.R. Brito, et al.
Methylation of P16, P21, P27 RB1 and P53 genes in odontogenic keratocysts.
J Oral Pathol Med, 38 (2010), pp. 99-103
[21]
Gani F. Evaluation of Ki-67 and cyclin D1 expression in odontogenic keratocysts and orthokeratinised jaw cysts. 2013. Tesis Doctoral.
[22]
M.A. Alsaegh, H. Miyashita, T. Taniguchi, S.R. Zhu.
Odontogenic epithelial proliferation is correlated with COX-2 expression in dentigerous cyst and ameloblastoma.
Exp Ther Med, 13 (2017), pp. 247-253
[23]
R.A. Mendes, J.F.C. Carvalho, I. Van der Waal.
A comparative immunohistochemical analysis of COX-2, p53, and Ki-67 expression in keratocystic odontogenic tumors.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 111 (2011), pp. 333-339
[24]
J.C. De Vicente, A. Torre-Iturraspe, A.M. Gutiérrez, P. Lequerica-Fernández.
Immunohistochemical comparative study of the odontogenic keratocysts and other odontogenic lesions.
Med Oral Patol Oral Cir Bucal, 15 (2010), pp. 709-715
Copyright © 2021. Sociedad Española de Anatomía Patológica
Opciones de artículo
Herramientas
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos